Latest Insider Transactions at Ironwood Pharmaceuticals Inc (IRWD)
This section provides a real-time view of insider transactions for Ironwood Pharmaceuticals Inc (IRWD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IRONWOOD PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IRONWOOD PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2023
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,798
+1.49%
|
-
|
|
Sep 15
2023
|
Sravan Kumar Emany SVP, Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
36,072
+16.05%
|
$288,576
$8.32 P/Share
|
|
Aug 29
2023
|
Ronald Silver Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+5.33%
|
-
|
|
Aug 14
2023
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,045
-3.54%
|
$70,450
$10.04 P/Share
|
|
Aug 14
2023
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,976
-1.45%
|
$19,760
$10.04 P/Share
|
|
Jun 20
2023
|
Julie Mc Hugh |
BUY
Grant, award, or other acquisition
|
Direct |
22,350
+12.1%
|
-
|
|
Jun 20
2023
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
22,350
+15.17%
|
-
|
|
Jun 20
2023
|
Jay Shepard |
BUY
Grant, award, or other acquisition
|
Direct |
22,350
+17.94%
|
-
|
|
Jun 20
2023
|
Mark G Currie |
BUY
Grant, award, or other acquisition
|
Direct |
22,350
+3.95%
|
-
|
|
Jun 20
2023
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
22,350
+16.02%
|
-
|
|
Jun 20
2023
|
Andrew Dreyfus |
BUY
Grant, award, or other acquisition
|
Direct |
22,350
+11.68%
|
-
|
|
Jun 20
2023
|
Jon R Duane |
BUY
Grant, award, or other acquisition
|
Direct |
22,350
+16.38%
|
-
|
|
Jun 20
2023
|
Marla L Kessler |
BUY
Grant, award, or other acquisition
|
Direct |
22,350
+17.35%
|
-
|
|
Jun 15
2023
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,359
+1.41%
|
-
|
|
Jun 15
2023
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,586
+1.52%
|
-
|
|
May 30
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,632
-3.39%
|
$266,320
$10.7 P/Share
|
|
May 22
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
36,000
-4.39%
|
$360,000
$10.12 P/Share
|
|
May 22
2023
|
Andrew Davis SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,305
-2.79%
|
$63,050
$10.12 P/Share
|
|
May 22
2023
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
10,324
-3.11%
|
$103,240
$10.12 P/Share
|
|
May 08
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,148
-2.51%
|
$211,480
$10.62 P/Share
|
|
Mar 27
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
46,129
-5.19%
|
$461,290
$10.67 P/Share
|
|
Mar 15
2023
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,438
+1.52%
|
-
|
|
Mar 15
2023
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,677
+1.63%
|
-
|
|
Mar 08
2023
|
Ronald Silver Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,620
+20.99%
|
-
|
|
Mar 08
2023
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,595
+21.31%
|
-
|
|
Mar 08
2023
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,502
+24.74%
|
-
|
|
Mar 08
2023
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,668
+10.4%
|
-
|
|
Mar 08
2023
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
69,869
+17.41%
|
-
|
|
Mar 08
2023
|
Andrew Davis SVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,236
+24.76%
|
-
|
|
Mar 08
2023
|
Sravan Kumar Emany SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,236
+32.72%
|
-
|
|
Mar 03
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
33,756
-4.95%
|
$371,316
$11.22 P/Share
|
|
Feb 28
2023
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,049
-3.0%
|
$33,539
$11.31 P/Share
|
|
Feb 28
2023
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
9,854
-1.83%
|
$108,394
$11.31 P/Share
|
|
Feb 28
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
31,227
-2.2%
|
$343,497
$11.31 P/Share
|
|
Feb 28
2023
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
17,429
-2.51%
|
$191,719
$11.31 P/Share
|
|
Feb 28
2023
|
Andrew Davis SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,822
-1.19%
|
$20,042
$11.31 P/Share
|
|
Feb 28
2023
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,415
-2.49%
|
$37,565
$11.31 P/Share
|
|
Feb 27
2023
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,929
-2.8%
|
$32,219
$11.41 P/Share
|
|
Feb 27
2023
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
9,468
-1.7%
|
$104,148
$11.41 P/Share
|
|
Feb 27
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,004
-2.03%
|
$330,044
$11.41 P/Share
|
|
Feb 27
2023
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
16,746
-2.3%
|
$184,206
$11.41 P/Share
|
|
Feb 27
2023
|
Andrew Davis SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,751
-1.13%
|
$19,261
$11.41 P/Share
|
|
Feb 27
2023
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,282
-2.34%
|
$36,102
$11.41 P/Share
|
|
Jan 17
2023
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,145
+3.9%
|
-
|
|
Jan 17
2023
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,087
+4.7%
|
-
|
|
Jan 17
2023
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
14,663
+4.96%
|
-
|
|
Jan 05
2023
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
110,962
-13.48%
|
$1,331,544
$12.07 P/Share
|
|
Jan 05
2023
|
Thomas A Mccourt Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
110,962
+11.88%
|
$1,220,582
$11.65 P/Share
|
|
Dec 15
2022
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,244
+1.33%
|
-
|
|
Dec 14
2022
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,000
-7.19%
|
$324,000
$12.39 P/Share
|